Cargando…
Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition
Despite effective antibiotic therapy, about one-third of patients admitted to an intensive care unit (ICU) with severe community-acquired pneumonia (CAP) and organ dysfunction die within a month. This high death rate demonstrates the need for additional interventions. Both animal models and clinical...
Autor principal: | Laterre, Pierre-Francois |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607114/ https://www.ncbi.nlm.nih.gov/pubmed/19105797 http://dx.doi.org/10.1186/cc7027 |
Ejemplares similares
-
Severe community acquired pneumonia update: mortality, mechanisms and medical intervention
por: Laterre, Pierre-Francois
Publicado: (2008) -
A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia
por: Laterre, Pierre-François, et al.
Publicado: (2009) -
Severe community-acquired pneumonia
por: Morgan, AJ, et al.
Publicado: (2016) -
Severe Community-Acquired Pneumonia
por: Khatib, Khalid, et al.
Publicado: (2019) -
Severe Community-Acquired Pneumonia
por: Sligl, Wendy I., et al.
Publicado: (2013)